As GLP-1 medications have become more widely prescribed, anesthesiologists have raised a specific, well-documented concern: the same mechanism that helps these drugs control appetite — delayed stomach emptying — can also leave food or liquid in the stomach longer than usual, raising the risk of aspiration during general anesthesia. Multiple medical societies have issued guidance on how to manage this risk around surgery.
The Concern: Delayed Gastric Emptying
GLP-1 receptor agonists slow the rate at which the stomach empties into the small intestine, part of how they reduce appetite and blood sugar spikes. That same effect means a patient who has fasted for the usual number of hours before surgery may still have more stomach contents than expected. Under general anesthesia, that raises the risk of regurgitation and aspiration — inhaling stomach contents into the airway and lungs — a serious and potentially fatal complication. The Anesthesia Patient Safety Foundation has published case reports describing retained solid gastric contents found unexpectedly during procedures in patients taking GLP-1 drugs.
What the 2023 ASA Guidance Said
The American Society of Anesthesiologists issued its first consensus-based guidance on this question in June 2023, flagging the aspiration risk and recommending anesthesiologists factor GLP-1 use into preoperative assessment, without settling on a single fixed rule for every patient.
The 2024 Multi-Society Update
A more detailed multi-society consensus statement followed in 2024. It concluded that most patients on GLP-1 medications can continue taking them before elective surgery, rather than stopping automatically, but recommended a stricter approach for patients considered higher risk: a liquid-only diet for the 24 hours before the procedure, and, where available, a point-of-care ultrasound just before surgery to check for retained stomach contents.
Who’s Considered Higher Risk
The guidance identifies several groups warranting extra caution: patients still in the first four to eight weeks of starting or increasing their GLP-1 dose, patients currently experiencing GI symptoms like nausea, vomiting, or constipation, patients on higher doses, and patients with other conditions that independently slow stomach emptying, such as Parkinson’s disease. For these groups, the guidance suggests deferring elective surgery until the risk factors resolve, where that’s medically reasonable.
What This Means for Patients
This is a rapidly evolving area of perioperative medicine, and specific recommendations continue to be refined as more data comes in, including a multidisciplinary consensus statement from the Society for Perioperative Assessment and Quality Improvement that has further updated some of this guidance. The core takeaway for patients isn’t a fixed rule to self-apply — it’s that GLP-1 use is relevant information a surgical and anesthesia team needs in advance.
Talk to Your Care Team
Anyone on a GLP-1 medication with upcoming surgery, even a minor or outpatient procedure, should tell both their surgeon and their anesthesiologist, and follow whatever preoperative fasting or dietary instructions they’re given specifically, rather than assuming a standard fasting window applies. This is exactly the kind of decision that depends on individual risk factors and should be made with a doctor, not inferred from general guidance like this article.